References
- Griffiths PD. Cytomegalovirus. In: Zuckerman AZ, editor. Principles and practice of clinical virology. 6th ed. Hoboken: Wiley; 2009. p. 161–98.
- Krech U. Complement-fixing antibodies against cytomegalovirus in different parts of the world. Bull World Health Organ. 1973;49:103–6.
- Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4:725–38.
- Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91:119–26.
- Rubin RH. Impact of cytomegalovirus infection on organ trans-plant recipients. Rev Infect Dis. 1990;12:S754–66.
- Mori T, Kameda H, Ogawa H, et al. Incidence of cytomegalo-virus reactivation in patients with inflammatory connective tissue disease who are under immunosuppressive therapy. J Rheumatol. 2004;31:1349–51.
- Yoda Y, Hanaoka R, Ide H, et al. Clinical evaluation of patients with inflammatory connective tissue diseases complicated by cytomegalovirus antigenemia. Mod Rheumatol. 2006;16:137–42.
- Takizawa Y, Inokuma S, Tanaka Y, et al. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre sur-vey in a large patient population. Rheumatology. 2008;47:1373–8.
- Kurihara T, Hayashi J, Matsuoka T, Ito A. HCMV pp65 antige-nemia assay using indirect alkaline phosphatase staining method. Biomed Res. 1995;16:125–9.
- Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094–7.
- Yamashita M, Ishii T, Iwama N, Takahashi H. Incidence and clinical features of cytomegalovirus infection diagnosed by cytomegalovirus pp65 antigenemia assay during high dose cor-ticosteroid therapy for collagen vascular diseases. Clin Exp Rheumatol. 2006;24:649–55.
- Diicke WD, Prösch S, Fietze E, et al. Cytomegalovirus reacti-vation and tumor necrosis factor. Lancet. 1994;343:268–9.
- Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300:413–22.
- Raftery MJ, Schwab M, Ebert SM, Samstag Y, Walczak H, Schönrich G. Targeting the function of mature dendritic cells by human cytomegalovirus: a multilayered viral defense strategy. Immunity. 2001;15:997–1009.
- Boeckh M, Nichols WG. Immunosuppressive effects of bet-aherpesviruses. Herpes. 2003;10:12–6.
- Varani S, Frascaroli G, Landini MP, Soderberg-Nauclér C. Human cytomegalovirus targets different subsets of antigen-presenting cells with pathological consequences for host immu-nity: implications for immunosuppression, chronic inflammation and autoimmunity. Rev Med Virol. 2009;19:131–45.
- van den Berg AP, Klompmaker U, Haagsma EB, et al. Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transplant. 1996;10: 224–31.
- George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Am J Med. 1997;103:106–13.
- Nichols WG, Corey L, Gooley T, Davis C, Boeckh M. High risk of death due to bacterial and fungal infection among cytomega-lovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection. J Infect Dis. 2002;185:273–82.
- Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet. 2005;365:2105–15.
- Compton T, Kurt-Jones EA, Boehme KW, et al. Human cyto-megalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol. 2003;77:4588–96.
- Fasth AE, Snir 0, Johansson AA, et al. Skewed distribution of proinflammatory CD4+ CD28 null T cells in rheumatoid arthri-tis. Arthritis Res Ther. 2007;9:R87.
- Zhu H, Cong JP, Yu D, Bresnahan WA, Shenk TE. Inhibition of cyclooxygenase2 blocks human cytomegalovirus replication. Proc Natl Acad Sci USA. 2002;99: 3932–7.
- Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet. 1994;344:1737–8.
- Cainelli F, Vento S. Infections and solid organ transplant rejec-tion: a cause-and-effect relationship? Lancet Infect Dis. 2002;2: 539–49.
- Sagedal S, Nordal KP, Hartmann A, et al. The impact of cyto-megalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant. 2002;2:850–6.